Intravenous BPC-157: What a Two-Person Safety Pilot Reported
An IRB-approved pilot monitored two adults during intravenous BPC-157 infusions, primarily to describe short-term tolerability and selected laboratory measurements.
Study design
Two participants who had previously received intravenous BPC-157 underwent baseline testing, a 10 mg infusion, repeat testing, and a 20 mg infusion on the following day. Vital signs, selected blood markers and self-reported side effects were recorded.
What the researchers reported
The investigators reported no measured changes in the selected heart, liver, kidney, thyroid or glucose markers and no participant-reported side effects during the short observation period.
What this result does not establish
Two previously exposed participants cannot provide a meaningful estimate of safety, rare events or longer-term risk. The report does not establish clinical benefit and should not be generalised beyond its narrow observations.
This article summarizes one published study about BPC-157. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.
Related research material
Review the corresponding catalogue listing, labelled amount and available documentation. The study may use a different formulation or experimental preparation; it does not verify our product, its batch or suitability for human use.
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards